Most ophthalmologists and industry followers can point to products that have ridden this wave.
Xiamen University’s 1,500-bed facility is the largest project underway.
Preregistration is up 21 percent over the 2014 total for the world’s biggest ophthalmic conference.
The meeting offers ample coverage of promising retinal products, but dry eye treatments and glaucoma drugs receive little attention.
Third Phase III trial did not include endpoints that objectively measured improvement in signs.
The firm faces three US government probes and was forced to cut ties with a specialty pharmacy that generated significant revenues for Valeant.
Segment is forecast to grow to $906 million at the manufacturer level by 2020.
A deal would be the largest takeover in a record-setting year for mergers and acquisitions.
The companies face additional legal challenges, including a Utah law prohibiting their minimum pricing policies.
EV06 is being developed to reverse age-related changes in the crystalline lens that result in diminished lens elasticity.
Many recent mergers in the pharmaceutical industry have been fueled by the low tax rates and loopholes in countries such as Luxemburg, Canada, and Ireland.
The device gained Health Canada approval and CE marking earlier in the year.
Early responses suggest that 18 percent plan to offer the lenses to all patients.
You are not currently logged in.
©2017 Market Scope
Lost your Password